XNYS
PRGO
Market cap1.42bUSD
Jun 18, Last price
10.25USD
1D
0.89%
1Q
10.81%
Jan 2017
-87.68%
Name
Perrigo Company PLC
Chart & Performance
P/E
—
P/S
0.32
EPS
—
Div Yield, %
11.32%
Shrs. gr., 5y
0.13%
Rev. gr., 5y
-2.00%
Revenues
4.37b
-6.06%
Net income
-172m
L+1,252.76%
CFO
363m
-10.51%
Dividend
Nov 28, 20250.29 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Perrigo Company plc is dedicated to delivering over-the-counter (OTC) health and wellness products designed to enhance personal well-being. The company's goal is to equip consumers with the means to proactively address or manage health conditions they can treat themselves. Its operations are organized into two key divisions: Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas division concentrates on the creation, production, promotion, and sale of store-brand self-care items throughout the United States, Mexico, Canada, and South America. This segment offers a broad spectrum of products, encompassing solutions for upper respiratory issues, pain relief and sleep assistance, digestive health, nutritional supplements (including vitamins and minerals), healthy lifestyle goods, skincare and personal hygiene products, and oral care. Notable brands within this portfolio include Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. Meanwhile, the Consumer Self-Care International division focuses on developing, manufacturing, marketing, and distributing its self-care brands to roughly 23 countries, primarily across Europe. These products reach consumers via an extensive network of pharmacies, wholesalers, drugstores, grocery retailers, and para-pharmacies. In addition to its proprietary offerings, Perrigo Company plc also provides contract manufacturing services. The company, established in 1887, has its global headquarters located in Dublin, Ireland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||